Pages that link to "Q24630309"
Jump to navigation
Jump to search
The following pages link to Genomewide pharmacogenomic study of metabolic side effects to antipsychotic drugs (Q24630309):
Displaying 50 items.
- Genome-wide association study of d-amphetamine response in healthy volunteers identifies putative associations, including cadherin 13 (CDH13) (Q21134099) (← links)
- Pharmacogenomics discovery and implementation in genome-wide association studies era (Q27001573) (← links)
- When drug discovery meets web search: Learning to Rank for ligand-based virtual screening (Q27902275) (← links)
- Treatment-resistant schizophrenia: current insights on the pharmacogenomics of antipsychotics (Q28079065) (← links)
- Progress in understanding the genomic basis for adverse drug reactions: a comprehensive review and focus on the role of ethnicity (Q28083100) (← links)
- Association between common variants near the melanocortin 4 receptor gene and severe antipsychotic drug-induced weight gain (Q28266158) (← links)
- Genotype-based ancestral background consistently predicts efficacy and side effects across treatments in CATIE and STAR*D (Q28486019) (← links)
- BCL9 and C9orf5 are associated with negative symptoms in schizophrenia: meta-analysis of two genome-wide association studies (Q28943394) (← links)
- Schizophrenia. (Q30251961) (← links)
- Genetic regulation of Nrxn1 [corrected] expression: an integrative cross-species analysis of schizophrenia candidate genes (Q30468815) (← links)
- Pharmacogenetics of antipsychotics (Q33836837) (← links)
- Genetic determinants of lipid traits in diverse populations from the population architecture using genomics and epidemiology (PAGE) study (Q33954461) (← links)
- DNA methylation changes in the postmortem dorsolateral prefrontal cortex of patients with schizophrenia (Q34088110) (← links)
- Improving metabolic and cardiovascular health at an early psychosis intervention program in vancouver, Canada (Q34139645) (← links)
- Replication of SULT4A1-1 as a pharmacogenetic marker of olanzapine response and evidence of lower weight gain in the high response group (Q34155219) (← links)
- Pharmacogenomic study of side-effects for antidepressant treatment options in STAR*D. (Q34229109) (← links)
- Glucagon-like peptide 1 receptor (GLP1R) haplotypes correlate with altered response to multiple antipsychotics in the CATIE trial (Q34644655) (← links)
- Antipsychotic drugs and obesity (Q34648940) (← links)
- Pharmacogenetics and antipsychotics: therapeutic efficacy and side effects prediction (Q34676533) (← links)
- Association of genetic variation with systolic and diastolic blood pressure among African Americans: the Candidate Gene Association Resource study (Q34955404) (← links)
- The impact of clinical heterogeneity in schizophrenia on genomic analyses (Q35019791) (← links)
- SOX5 is a candidate gene for chronic obstructive pulmonary disease susceptibility and is necessary for lung development. (Q35107672) (← links)
- Horizons of psychiatric genetics and epigenetics: where are we and where are we heading? (Q35177686) (← links)
- Analysis of efficacy and side effects in CATIE demonstrates drug response subgroups and potential for personalized medicine (Q35375788) (← links)
- Genome-wide association studies in Africans and African Americans: expanding the framework of the genomics of human traits and disease (Q35565624) (← links)
- Genome-wide pharmacogenomic study of citalopram-induced side effects in STAR*D. (Q36135959) (← links)
- Pharmacogenetics of antipsychotics: recent progress and methodological issues (Q36539833) (← links)
- Genome-Wide Meta-Analysis of Longitudinal Alcohol Consumption Across Youth and Early Adulthood (Q36604310) (← links)
- Scientific challenges and implementation barriers to translation of pharmacogenomics in clinical practice (Q36702588) (← links)
- Mechanisms and Disease Associations of Haplotype-Dependent Allele-Specific DNA Methylation (Q36891490) (← links)
- Moderation of antipsychotic-induced weight gain by energy balance gene variants in the RUPP autism network risperidone studies. (Q36956632) (← links)
- Validation of candidate genes associated with cardiovascular risk factors in psychiatric patients (Q37016538) (← links)
- Single nucleotide polymorphisms in the REG-CTNNA2 region of chromosome 2 and NEIL3 associated with impulsivity in a Native American sample (Q37072122) (← links)
- Silencing of the Drosophila ortholog of SOX5 in heart leads to cardiac dysfunction as detected by optical coherence tomography (Q37111971) (← links)
- Genotypic variation in the SV2C gene impacts response to atypical antipsychotics the CATIE study (Q37353278) (← links)
- Genome-wide association study of patient-rated and clinician-rated global impression of severity during antipsychotic treatment (Q37581282) (← links)
- Pharmacogenetics of antipsychotic-induced weight gain: review and clinical implications. (Q37926893) (← links)
- Pharmacogenetics of response to antipsychotics in patients with schizophrenia (Q37952823) (← links)
- Pharmacogenetics in psychiatry: translating research into clinical practice. (Q37956206) (← links)
- Toward understanding genetic risk for differential antipsychotic response in individuals with schizophrenia (Q37960512) (← links)
- Integrative genomics strategies to elucidate the complexity of drug response (Q37961088) (← links)
- Strengths and weaknesses of pharmacogenetic studies of antipsychotic drugs: the potential value of the PEPs study. (Q38061501) (← links)
- Pharmacogenetics of clinical response to risperidone. (Q38074712) (← links)
- Pharmacogenetic Aspects of Antipsychotic Drug-induced Weight Gain - A Critical Review (Q38083647) (← links)
- Pharmacogenomics can improve antipsychotic treatment in schizophrenia (Q38100731) (← links)
- The multidimensional nature of metabolic syndrome in schizophrenia: lessons from studies of one-carbon metabolism and DNA methylation (Q38113237) (← links)
- Pharmacogenetics of antidepressants, mood stabilizers, and antipsychotics in diverse human populations (Q38133628) (← links)
- Pharmacogenetics in schizophrenia: a review of clozapine studies (Q38154175) (← links)
- Individualizing clozapine and risperidone treatment for schizophrenia patients (Q38170458) (← links)
- Pharmacogenetics of second-generation antipsychotics (Q38217628) (← links)